Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

PD-1/ PD-L1 pathway in suppressing anti-tumor immunity

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Slide 3

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Nivolumab <br />(ONO4538/BMS936558)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Study design: Investigator initiated, 2 cohorts Phase II

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Key inclusion criteria

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Study schedule

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Demographics

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Adverse events: Regardless of causality <br /> (>=4 patients)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Slide 10

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Serious adverse events<br />(Treatment-related)

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Clinical Effect : Best Overall Response

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

A Responder with Serous adenoca : <br />Nivolumab 3mg/kg

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

A Responder with Clear cell carcinoma :<br />Nivolumab 3mg/kg

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Best overall responses in all patients

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Best overall responses in all patients in 2 cohorts

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Summary

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Conclusions

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Acknowledgements

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Research group

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Slide 21

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Clinical Effect : Response Duration

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Best overall responses in all patients

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting

Slide 24

Presented By Junzo Hamanishi at 2014 ASCO Annual Meeting